The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men .
OBJECTIVES Ageing in men is associated with a gradual decline in serum testosterone levels and a concomitant loss of muscle mass , accumulation of central adiposity , impaired mobility and increased risk of bone fractures .
Whether and rogen treatment might be beneficial in these subjects is still under debate .
We have carried out a systematic review of r and omized controlled trials ( RCTs ) evaluating the effects of testosterone ( T ) administration  to middle-aged and ageing men on body composition , muscle strength , bone density , markers of bone metabolism and serum lipid profile .
Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study.
BACKGROUND AND METHODS In order to assess the effects of testosterone undecanoate ( TU ; 120 mg/d orally for 2 months ) on serum lipid , lipoprotein , and apolipoprotein levels in healthy elderly men , the  placebo ( PL ) controlled study was performed on 37 elderly men , aged between 53 and 89 years . In all subjects venous blood sample s were taken after an overnight ( 10 hours ) fast and sera were stored -70 degrees C until analysis . RESULTS In PL group , neither hormonal data nor lipid , lipoprotein , and apolipoprotein levels showed significant changes . After TU supplementation , serum total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , and estradiol ( E2 ) levels decreased from 198 + /- 30.7 mg/dl to 174 + /- 41.9 mg/dl ( p < 0.05 ) , from 111 + /- 18.14 mg/dl to 87.9 + /- 29.4 mg/dl ( p < 0.01 ) , and from 86.2 + /- 16.9 pmol/l to 70.5 + /- 18 pmol/l ( p < 0.01 ) , respectively . Statistically significant differences were not observed in the serum triglyceride ( TG ) , high-density lipoprotein cholesterol ( HDL-C ) , and apolipoprotein ( apo ) A-1 and apo B levels after TU treatment . The mean ratios TC/HDL-C and LDL-C/HDL-C as coronary risk factor criteria decreased significantly in the TU but not in the PL group . No obvious side effect was observed in those who took TU except for reported pyrosis in 2 of 17 elderly men . CONCLUSIONS These data indicate that the increased serum levels of total testosterone ( TT ) produced by administration of TU , 120 mg/d orally for 2 months lead to suppressed levels of TC and LDL-C and E2 but not significantly changed levels of TC , HDL-C , apo A-1 and apo B. Thus , we conclude that TU may be an effective drug for protecting coronary heart disease in healthy elderly men with lowered TT and FT levels . It may also have beneficial effects for sexual function and behavior
The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men .
OBJECTIVES Ageing in men is associated with a gradual decline in serum testosterone levels and a concomitant loss of muscle mass , accumulation of central adiposity , impaired mobility and increased risk of bone fractures .
Whether and rogen treatment might be beneficial in these subjects is still under debate .
We have carried out a systematic review of r and omized controlled trials ( RCTs ) evaluating the effects of testosterone ( T ) administration  to middle-aged and ageing men on body composition , muscle strength , bone density , markers of bone metabolism and serum lipid profile .